{"filing":{"accession_number":"0001193125-26-302045","cik":"0001761918","ticker":"ERAS","company_name":"Erasca, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d54726d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/d54726d8k.htm"},"events":[{"id":17608,"run_id":15776,"accession_number":"0001193125-26-302045","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Erasca disclosed updated Phase 1 clinical trial data for ERAS-0015 showing encouraging monotherapy responses in KRAS G12X PDAC (57% uORR at RDE), consistent safety profile, and promising combination potential with panitumumab. The company also announced plans to initiate potentially registration-enabling Phase 3 trials in PDAC and NSCLC in 2027. This is a material clinical development milestone for a biotech company's lead candidate that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types—making it an operational/strategic business event.","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16151,"accession_number":"0001193125-26-302045","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Erasca disclosed updated Phase 1 clinical trial data for ERAS-0015 showing encouraging monotherapy responses in KRAS G12X PDAC (57% uORR at RDE), consistent safety profile, and promising combination potential with panitumumab. The company also announced plans to initiate potentially registration-enabling Phase 3 trials in PDAC and NSCLC in 2027. This is a material clinical development milestone for a biotech company's lead candidate that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types—making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:20:38.242049+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16151,"accession_number":"0001193125-26-302045","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Erasca disclosed updated Phase 1 clinical trial data for ERAS-0015 showing encouraging monotherapy responses in KRAS G12X PDAC (57% uORR at RDE), consistent safety profile, and promising combination potential with panitumumab. The company also announced plans to initiate potentially registration-enabling Phase 3 trials in PDAC and NSCLC in 2027. This is a material clinical development milestone for a biotech company's lead candidate that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types—making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:20:38.242049+00:00","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-07-13"}]}